UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis
· UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) · UC is a chronic, inflammatory bowel disease with substantial unmet medical need for new oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2b results in psoriasis and Phase 2 results in hidradenitis suppurativa (HS); orismilast also recently completed enrollment in an ongoing Phase 2b study in atopic dermatitis Hellerup, Denmark, January 4, 2024 – UNION therapeutics A/